Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2018 | May 03, 2018 | |
Document And Entity Information [Abstract] | ||
Entity Registrant Name | ViewRay, Inc. | |
Entity Central Index Key | 1,597,313 | |
Document Type | 10-Q | |
Trading Symbol | VRAY | |
Document Period End Date | Mar. 31, 2018 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Accelerated Filer | |
Entity Common Stock, Shares Outstanding | 75,084,219 | |
Document Fiscal Period Focus | Q1 | |
Document Fiscal Year Focus | 2,018 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Current assets: | ||
Cash and cash equivalents | $ 78,916 | $ 57,389 |
Accounts receivable | 26,171 | 20,326 |
Inventory | 30,441 | 19,375 |
Deposits on purchased inventory | 10,001 | 7,043 |
Deferred cost of revenue | 4,110 | 13,696 |
Prepaid expenses and other current assets | 4,374 | 4,862 |
Total current assets | 154,013 | 122,691 |
Property and equipment, net | 12,955 | 11,564 |
Restricted cash | 1,143 | 1,143 |
Intangible assets, net | 73 | 78 |
Other assets | 441 | 235 |
TOTAL ASSETS | 168,625 | 135,711 |
Current liabilities: | ||
Accounts payable | 13,443 | 11,014 |
Accrued liabilities | 7,897 | 7,207 |
Customer deposits | 9,620 | 17,820 |
Deferred revenue, current portion | 9,670 | 20,151 |
Total current liabilities | 40,630 | 56,192 |
Deferred revenue, net of current portion | 3,343 | 3,238 |
Long-term debt | 44,551 | 44,504 |
Warrant liabilities | 14,238 | 22,420 |
Other long-term liabilities | 8,199 | 7,370 |
TOTAL LIABILITIES | 110,961 | 133,724 |
Commitments and contingencies (Note 6) | ||
Stockholders’ equity: | ||
Convertible preferred stock, par value of $0.01 per share; 10,000,000 shares authorized at March 31, 2018 and December 31, 2017; 3,000,581 shares issued and outstanding at March 31, 2018 and no shares issued and outstanding at December 31, 2017 | 30 | |
Common stock, par value of $0.01 per share; 300,000,000 shares authorized at March 31, 2018 and December 31, 2017; 72,022,089 and 67,653,974 shares issued and outstanding at March 31, 2018 and December 31, 2017 | 710 | 666 |
Additional paid-in capital | 384,319 | 321,174 |
Accumulated deficit | (327,395) | (319,853) |
TOTAL STOCKHOLDERS’ EQUITY | 57,664 | 1,987 |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ 168,625 | $ 135,711 |
Condensed Consolidated Balance3
Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares | Mar. 31, 2018 | Dec. 31, 2017 |
Statement Of Financial Position [Abstract] | ||
Preferred stock, par value per share | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 10,000,000 | 10,000,000 |
Preferred stock, shares issued | 3,000,581 | 0 |
Preferred stock, shares outstanding | 3,000,581 | 0 |
Common stock, par value per share | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 300,000,000 | 300,000,000 |
Common stock, shares issued | 72,022,089 | 67,653,974 |
Common stock, shares outstanding | 72,022,089 | 67,653,974 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Revenue: | ||
Product | $ 25,379 | $ 0 |
Service | 692 | 1,108 |
Distribution rights | 119 | 119 |
Total revenue | 26,190 | 1,227 |
Cost of revenue: | ||
Product | 19,711 | 266 |
Service | 909 | 776 |
Total cost of revenue | 20,620 | 1,042 |
Gross margin | 5,570 | 185 |
Operating expenses: | ||
Research and development | 3,770 | 2,914 |
Selling and marketing | 3,246 | 1,072 |
General and administrative | 9,846 | 7,151 |
Total operating expenses | 16,862 | 11,137 |
Loss from operations | (11,292) | (10,952) |
Interest income | 2 | 1 |
Interest expense | (1,866) | (1,737) |
Other income (expense), net | 8,342 | (15,273) |
Loss before provision for income taxes | (4,814) | (27,961) |
Provision for income taxes | 0 | 0 |
Net loss and comprehensive loss | (4,814) | (27,961) |
Amortization of beneficial conversion feature related to Series A convertible preferred stock | (2,728) | 0 |
Net loss attributable to common stockholders, basic and diluted | $ (7,542) | $ (27,961) |
Net loss per share, basic and diluted | $ (0.11) | $ (0.54) |
Weighted-average common shares used to compute net loss per share attributable to common stockholders, basic and diluted | 68,943,918 | 51,821,422 |
Condensed Consolidated Stateme5
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | Dec. 31, 2017 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | |||
Net loss | $ (4,814) | $ (27,961) | |
Adjustments to reconcile net loss to net cash used in operating activities: | |||
Depreciation and amortization | 658 | 467 | |
Stock-based compensation | 1,190 | 769 | |
Accretion on asset retirement obligation | 10 | 9 | |
Change in fair value of warrant liabilities | (8,182) | 15,231 | |
Loss on disposal of property and equipment | 0 | 6 | |
Amortization of debt discount and interest accrual | 870 | 785 | |
Changes in operating assets and liabilities: | |||
Accounts receivable | (5,845) | 928 | |
Inventory | (12,021) | (2,134) | |
Deposits on purchased inventory | (2,958) | (1,951) | |
Deferred cost of revenue | 9,126 | (2,341) | |
Prepaid expenses and other assets | 282 | (1,675) | |
Accounts payable | 2,081 | 560 | |
Accrued expenses and other long-term liabilities | 725 | (138) | |
Customer deposits and deferred revenue | (18,576) | 5,481 | |
Net cash used in operating activities | (37,454) | (11,964) | |
CASH FLOWS FROM INVESTING ACTIVITIES: | |||
Purchase of property and equipment | (497) | (319) | |
Net cash used in investing activities | (497) | (319) | |
CASH FLOWS FROM FINANCING ACTIVITIES: | |||
Proceeds from common stock private placement, gross | 0 | 26,100 | |
Proceeds from the exercise of stock options | 378 | 2 | |
Net cash provided by financing activities | 59,478 | 47,386 | |
NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | 21,527 | 35,103 | |
CASH, CASH EQUIVALENTS AND RESTRICTED CASH — BEGINNING OF PERIOD | 58,532 | 15,341 | $ 15,341 |
CASH, CASH EQUIVALENTS AND RESTRICTED CASH — END OF PERIOD | 80,059 | 50,444 | 58,532 |
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | |||
Cash paid for interest | 996 | 951 | |
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES: | |||
Purchase of property and equipment in accounts payable and accrued expenses | 228 | 135 | |
Transfer of property and equipment from inventory and deferred cost of revenue | 1,415 | 0 | |
Offering cost in accounts payable and accrued expenses | 177 | 394 | |
Private Placement | |||
CASH FLOWS FROM FINANCING ACTIVITIES: | |||
Payment of offering costs related to common stock issuance | 0 | (210) | |
At The Market Offering Program | |||
CASH FLOWS FROM FINANCING ACTIVITIES: | |||
Payment of offering costs related to common stock issuance | 0 | (427) | |
Proceeds from offering of common stock, gross | 0 | 21,921 | $ 40,100 |
Direct Registered Offering | |||
CASH FLOWS FROM FINANCING ACTIVITIES: | |||
Proceeds from offering of common stock, gross | $ 59,100 | $ 0 |
Background and Organization
Background and Organization | 3 Months Ended |
Mar. 31, 2018 | |
Organization Consolidation And Presentation Of Financial Statements [Abstract] | |
Background and Organization | 1. Background and Organization ViewRay, Inc., or ViewRay or the Company, and its wholly owned subsidiary ViewRay Technologies, Inc., designs, manufactures and markets MRIdian, an MR Image-Guided radiation therapy system to simultaneously image and treat cancer patients. Since inception, ViewRay Technologies, Inc. has devoted substantially all of its efforts towards research and development, initial selling and marketing activities, raising capital and the manufacturing and shipment of MRIdian systems. In May 2012, ViewRay Technologies, Inc. was granted clearance from the U.S. Food and Drug Administration, or FDA, to sell MRIdian with Cobalt-60. In November 2013, ViewRay Technologies, Inc. received its first clinical acceptance of a MRIdian with Cobalt-60 at a customer site, and the first patient was treated with that system in January 2014. ViewRay Technologies, Inc. has had the right to affix the CE mark to MRIdian with Cobalt-60 in the European Economic Area since November 2014. In September 2016, the Company received the rights to affix the CE mark to MRIdian Linac, and in February 2017, the Company received 510(k) clearance from the FDA to market MRIdian Linac. The Company’s condensed consolidated financial statements have been prepared on the basis of the Company continuing as a going concern for a reasonable period of time. The Company’s principal sources of liquidity are cash flows from public and private offerings of capital stock and available borrowings under its term loan agreement, as well as cash from the sale of its systems and services. These have historically been sufficient to meet working capital needs, capital expenditures, and debt service obligations. During the three months ended March 31, 2018, the Company incurred a net loss of $4.8 million, and used cash in operations of $37.5 million. The Company believes that its existing cash balance of $78.9 million as of March 31, 2018, together with anticipated cash receipts from sales of MRIdian systems is sufficient to fund its operations for at least the next 12 months. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2018 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | 2. Summary of Significant Accounting Policies Basis of Presentation The condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or GAAP, and pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. The condensed consolidated financial statements include the accounts of ViewRay, Inc. and its wholly owned subsidiary, ViewRay Technologies, Inc. All inter-company accounts and transactions have been eliminated in consolidation. In the opinion of management, all adjustments, including normal recurring adjustments, considered necessary for a fair presentation of the Company’s unaudited condensed consolidated financial statements, have been included. The results of operations for the three months ended March 31, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018 or any future period. These unaudited condensed consolidated financial statements and their notes should be read in conjunction with the audited consolidated financial statements and related notes for the year ended December 31, 2017. Effective January 1, 2018, the Company adopted Accounting Standard Codification Topic 606, or ASC 606, Revenues from Contracts with Customers, Significant Accounting Policies The significant accounting policies used in preparation of these condensed consolidated financial statements are disclosed in the notes to consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed with the SEC on March 12, 2018, and have not changed significantly since that filing, except for the impact of the adoption of the new accounting guidance related to revenue recognition. Revenue Recognition The Company derives revenues primarily from the sale of MRIdian systems and related services as well as support and maintenance services on sold systems. The Company accounts for revenue contracts with customers by applying the requirements of ASC 606, which includes the following steps: • Identification of the contract, or contracts, with a customer; • Identification of the performance obligations in the contract; • Determination of the transaction price; • Allocation of the transaction price to the performance obligations in the contract; and • Recognition of revenue when, or as, the Company satisfies a performance obligation. In all sales arrangements, revenues are recognized when control of the promised goods or services are transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those goods or services. For sales of MRIdian systems that the Company is required to install at the customer site, product revenue is recognized upon receipt of customer acceptance. For sales of MRIdian systems for which the Company is not responsible for installing, product revenue is recognized when the entire system is delivered and control of the system is transferred to the customer. For sales of the related support and maintenance services, a time-elapsed method is used to measure progress toward complete satisfaction of performance obligations and service revenue is recognized ratably over the service contract term, which is typically 12 months. Arrangements with Multiple Performance Obligation The Company frequently enters into sales arrangements that include multiple performance obligations, which mainly consist of (i) sale of MRIdian systems, which generally includes installation and embedded software, and (ii) product support, which includes extended service and maintenance. For such arrangements, the Company allocates revenue to each performance obligation based on its relative standalone selling price. The standalone selling price, or SSP, is determined based on observable prices at which the Company separately sells the products and services. If an SSP is not directly observable, the Company will estimate the SSP considering market conditions or internally approved pricing guidelines related to the performance obligations. Product Revenue Product revenue is derived primarily from the sales of MRIdian system. The system contains both software and non-software components that together deliver essential functionality. The Company’s customer contracts generally call for on-site assembly of the system components and system integration. Once the system installation is completed, the Company performs a detailed demonstration with the customer showing that the MRIdian system meets the standard product specifications. After successful demonstration, the customer signs a document indicating customer’s acceptance. For sales of MRIdian systems that the Company is required to install at the customer site, revenue recognition occurs when the customer acknowledges that the system operates in accordance with standard product specifications, the customer accepts the installed unit by signing the acceptance document and the control of the system is transferred to the customer. Certain customer contracts with distributors do not require ViewRay installation at the customer site, and the distributors typically have their own or engage a qualifying third-party certified technician to perform the installation. For sales of MRIdian systems for which the Company is not responsible for installation, revenue recognition occurs when the entire system is delivered and the control of the system is transferred to the customer. Service Revenue Service revenue is derived primarily from maintenance services. The maintenance and support service is a stand-ready obligation which is performed over the term of the arrangement and, as a result, service revenue is recognized ratably over the service period as the customers benefit from the service throughout the service period. Distribution Rights Revenue In December 2014, the Company entered into a distribution agreement with Itochu Corporation pursuant to which it appointed Itochu as its exclusive distributor for the promotion, sale and delivery of MRIdian products within Japan. In consideration of the exclusive distribution rights granted, the Company received $4.0 million, which was recorded as deferred revenue. Starting in August 2016, distribution rights revenue is recognized ratably over the remaining term of the distribution agreement of approximately 8.5 years . The following table presents revenue disaggregated by types and geography (in thousands): Three Months Ended March 31, U.S. 2018 2017 Product $ 13,535 $ — Service 396 879 Total U.S. revenue $ 13,931 $ 879 Outside of U.S. ("OUS") Product $ 11,844 $ — Service 296 229 Distribution rights 119 119 Total OUS revenue $ 12,259 $ 348 Total Product $ 25,379 $ — Service 692 1,108 Distribution rights 119 119 Total revenue $ 26,190 $ 1,227 Contract Balances The timing of revenue recognition, billings and cash collections results in trade receivables, customer deposit, deferred revenues and deferred cost of revenue on the condensed consolidated balance sheets. Customer deposits represent payments received in advance of system installation. For domestic and international sales, advance payments received prior to inventory shipments and customer acceptance are recorded as customer deposits. Advance payments are subsequently reclassified to deferred revenue upon inventory shipment when the title and risk of loss of inventory items transfer to customers. All customer deposits, including those that are expected to be a deposit for more than one year, are classified as current liabilities based on consideration of the Company’s normal operating cycle (the time between acquisition of the inventory components and the final cash collection from customers on these inventory components) which is in excess of one year. Deferred revenue consists of deferred product revenue and deferred service revenue. Deferred product revenue arises from timing differences between the fulfillment of other contract obligation and satisfaction of all revenue recognition criteria consistent with the Company’s revenue recognition policy. Deferred service revenue results from the advance billing for services to be delivered over a period of time. Deferred revenues expected to be realized within one year or normal operating cycle are classified as current liabilities. Deferred cost of revenue consists of cost for inventory items that have been shipped with title and risk of loss transferred to the customer, but the customer acceptance has not been received. Deferred cost of revenue is included as part of current assets as the corresponding deferred product revenue is expected to be realized within one year or normal operating cycle. During the three months ended March 31, 2018 and 2017, the Company recognized $22.2 million and $0.4 million revenue that was included in the deferred revenue balance at the beginning of each reporting period. Practical Expedients Election As part of the Company's adoption of ASC 606, the Company elected to use the practical expedient to expense costs to obtain a contract as incurred when the amortization period would have been one year or less, which mainly includes the Company's internal sales force compensation program. Recent Accounting Pronouncements In February 2016, the Financial Accounting Standards Board, FASB, issued ASU No. 2016-02, Leases (Topic 842) Recently Adopted Accounting Pronouncements In May 2014, the FASB issued ASC 606. Under the standard, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services. Effective January 1, 2018, the Company adopted the requirements of ASC 606 using the full retrospective method. The adoption has no impact on the prior period financial statements, and the related disclosures required by the new standard have been updated in the “Significant Accounting Policies” section above. On January 1, 2018, the Company adopted ASU No.2016-15 , Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments Statement of Cash Flows (Topic 230): Restricted Cash Under ASU 2016-18, restricted cash and restricted cash equivalent amounts are presented along with cash and cash equivalents when reconciling the total beginning and ending amounts shown on the statement of cash flows. The Company reflected the impact of ASU No. 2016-18 to the comparative prior period which resulted in an increase in the beginning and ending cash, cash equivalents and restricted cash of $ In May 2017, the FASB issued ASU No. 2017-09 , Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting In the first quarter of 2018, the Company adopted ASU No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118, |
Balance Sheet Components
Balance Sheet Components | 3 Months Ended |
Mar. 31, 2018 | |
Organization Consolidation And Presentation Of Financial Statements [Abstract] | |
Balance Sheet Components | 3. Balance Sheet Components Property and Equipment Property and equipment consisted of the following (in thousands): March 31, 2018 December 31, 2017 Prototype $ 11,938 $ 11,929 Machinery and equipment 9,731 7,831 Leasehold improvements 4,565 4,438 Software 1,120 1,142 Furniture and fixtures 588 558 Property and equipment, gross 27,942 25,898 Less: accumulated depreciation and amortization (14,987 ) (14,334 ) Property and equipment, net $ 12,955 $ 11,564 Depreciation and amortization expense related to property and equipment were $653 thousand and $462 thousand during the three months ended March 31, 2018 and 2017, respectively. Intangible Assets Intangible assets consisted of the following (in thousands): March 31, 2018 December 31, 2017 License cost $ 512 $ 512 Patents 104 104 Intangible assets, gross 616 616 Accumulated amortization (543 ) (538 ) Intangible assets, net $ 73 $ 78 Intangible assets amortization expense was $5,000 At March 31, 2018, the estimated future amortization expense of intangible assets was as follows (in thousands): Year Ending December 31, Estimated Amortization Expense The remainder of 2018 $ 14 2019 19 2020 19 2021 10 2022 3 2023 1 Thereafter 7 Total amortization expense $ 73 Accrued Liabilities Accrued liabilities consisted of the following (in thousands): March 31, 2018 December 31, 2017 Accrued payroll and related benefits $ 5,062 $ 3,944 Accrued accounts payable 2,180 2,671 Accrued legal, accounting and governance fees 198 322 Tax payable 401 149 Other 56 121 Total accrued liabilities $ 7,897 $ 7,207 Deferred Revenue Deferred revenue consisted of the following (in thousands): March 31, 2018 December 31, 2017 Deferred revenue: Product $ 6,551 $ 18,861 Services 3,234 1,182 Distribution rights 3,228 3,346 Total deferred revenue 13,013 23,389 Less: current portion of deferred revenue (9,670 ) (20,151 ) Noncurrent portion of deferred revenue $ 3,343 $ 3,238 |
Fair Value of Financial Instrum
Fair Value of Financial Instruments | 3 Months Ended |
Mar. 31, 2018 | |
Fair Value Disclosures [Abstract] | |
Fair Value of Financial Instruments | 4. Fair Value of Financial Instruments The Company’s financial instruments that are carried at fair value mainly consist of Level 1 assets and Level 3 liabilities. Level 1 assets include highly liquid bank deposits and money market funds, which were not material at March 31, 2018 and December 31, 2017. Level 3 liabilities that are measured on a recurring basis consist of the 2017 and 2016 Placement Warrants, as described in Note 8. Placement warrant liabilities are valued using the Black-Scholes option-pricing model. Generally, increases (decreases) in the fair value of the underlying stock and estimated term would result in a directionally similar impact to the fair value of the warrants (see Note 10). The gains and losses from re-measurement of Level 3 financial liabilities are recorded as part of other income (expense), net in the condensed consolidated statements of operations. During the three months ended March 31, 2018 and 2017, the Company recorded a gain of $8.2 million and a loss of $15.2 million, respectively, related to the change in fair value of the 2017 and 2016 Placement Warrants. There have been no transfers between Level 1, Level 2 and Level 3 in any periods presented. The following table sets forth the fair value of the Company’s financial liabilities by level within the fair value hierarchy (in thousands): At March 31, 2018 Level 1 Level 2 Level 3 Total 2017 Placement Warrants Liability $ — $ — $ 7,932 $ 7,932 2016 Placement Warrants Liability — — 6,306 6,306 Total $ — $ — $ 14,238 $ 14,238 At December 31, 2017 Level 1 Level 2 Level 3 Total 2017 Placement Warrants Liability $ — $ — $ 12,487 $ 12,487 2016 Placement Warrants Liability — — 9,933 9,933 Total $ — $ — $ 22,420 $ 22,420 The following table sets forth a summary of the changes in fair value of the Company’s Level 3 financial liabilities (in thousands): Three Months Ended March 31, 2018 2017 Fair value, beginning of period $ 22,420 $ 2,723 Issuance of 2017 Placement Warrants — 3,373 Change in fair value of Level 3 financial liabilities (8,182 ) 15,231 Fair value, end of period $ 14,238 $ 21,327 |
Debt
Debt | 3 Months Ended |
Mar. 31, 2018 | |
Debt Instruments [Abstract] | |
Debt | 5. Debt CRG Term Loan In June 2015, ViewRay Technologies, Inc. entered into a Term Loan Agreement, or the CRG Term Loan, with Capital Royalty Partners II L.P., Capital Royalty Partners II – Parallel Fund “A” L.P., Capital Royalty Partners II (Cayman) L.P. and Parallel Investment Opportunities Partners II L.P. or together with their successors by assignment, CRG, for up to $50.0 million of which $30.0 million was made available to the Company upon closing with the remaining $20.0 million available on or before June 26, 2016 at its option upon the occurrence of either: (i) an initial public offering of its common stock on a nationally recognized securities exchange that raises a minimum of $40.0 million in net cash proceeds with a minimum of $120.0 million post-money valuation, or Qualifying IPO, or (ii) achievement of a minimum of $25.0 million gross revenue from the sales of the MRIdian system during any consecutive 12 months before March 31, 2016. The Company drew down the first $30.0 million on the closing date. The CRG Term Loan has a maturity date of June 26, 2020 and bears cash interest at a rate of 12.5% per annum to be paid quarterly during the interest-payment-only period of 3 years. In April 2017, the CRG Term Loan was amended to allow for interest-payment-only until March 31, 2020. During the interest-payment-only period, the Company has the option to elect to pay only 8% of the 12.5% per annum interest in cash, and the remaining 4.5% of the 12.5% per annum interest as compounded interest, or deferred payment in-kind interest, added to the aggregate principal amount of the CRG Term Loan. Principal payment and any deferred payment in-kind interest will be paid quarterly in equal installments following the end of the interest-payment-only period through maturity date. The CRG Term Loan is subject to a prepayment penalty of: 3% on the outstanding balance during the first 12 months following the funding of the Term Loan; 2% on the outstanding balance after year 1 but on or before year 2; 1% on the outstanding balance after year 2 but on or before year 3; and 0% on the outstanding loan if prepaid after year 3 thereafter until maturity. The Term Loan is also subject to a facility fee of 7% based on the sum of the amount drawn and any outstanding payment in-kind interest payable on the maturity date or the date the Term II loan becomes due. All direct financing costs were accounted for as a discount on the CRG Term Loan and will be amortized to interest expense during the life of the loan using the effective interest method. The CRG Term Loan is subject to financial covenants and is collateralized by essentially all assets of the Company and limits its ability with respect to additional indebtedness, investments or dividends, among other things, subject to customary exceptions. In March 2016, the Company and CRG executed an amendment to the original terms of the CRG Term Loan such that, with regard to the conditions for borrowing the remaining $20.0 million available under the CRG Term Loan, the Company may, at its election, draw down: (i) an amount of either $10.0 million or $15.0 million in up to two advances upon achievement of a minimum of $15.0 million of aggregate product and service revenue during any consecutive 12 month period ending on or before March 31, 2016; and (ii) an additional $5.0 million (or $10.0 million, if the previous draw made was only in an amount of $10.0 million) upon achievement of a minimum of $25.0 million of aggregate product and service revenue during any consecutive 12 month period ending on or before December 31, 2016 and upon execution of the first sales contract of the Company’s second generation product. The Company achieved the minimum of $15.0 million gross revenue requirement in March 2016, which made the first $15.0 million of the remaining $20.0 million credit facility immediately available for draw down. In May 2016, the Company drew down the additional $15.0 million available amount. In April 2017, the Company and CRG executed an amendment to the terms of its CRG Term Loan. Amendments to the CRG Term Loan include availability of the existing $5.0 million tranche at ViewRay’s option through June 30, 2017, the addition of a $15.0 million tranche of borrowing capacity available at ViewRay’s option through September 30, 2017, extension of the interest-only and payment in-kind period, a decrease to the combined 2016 and 2017 revenue covenant and a 1.75% increase to the facility fee. In October 2017, the Company and CRG executed another amendment to the terms of its CRG Term Loan, as amended in March 2016 and April 2017. This amendment extended the availability of the existing $15.0 million borrowing capacity through December 31, 2017. The Company did not draw down any amounts under the $5.0 million or the $15.0 million tranches and they have since expired. In February 2018, the Company and CRG executed an amendment to the terms of its CRG Term Loan to decrease the amount of the minimum combined 2016 and 2017 revenue covenant. At March 31, 2018, the Company had $45.0 million in outstanding debt and $5.3 million in deferred payment in-kind interest to CRG and was in compliance with all financial covenants under the CRG Term Loan. |
Commitments and Contingencies
Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2018 | |
Commitments And Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 6. Commitments and Contingencies Operating Leases The Company leases office space in Oakwood Village, Ohio and Mountain View, California under noncancelable operating leases. At March 31, 2018, the future minimum payments for the operating leases are as follows (in thousands): Year Ending December 31, Future Payments The remainder of 2018 $ 840 2019 1,039 Total future minimum payments $ 1,879 Contingencies The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred and the amount can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. In the normal course of business, the Company may become involved in legal proceedings. The Company will accrue a liability for legal proceedings when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The accrual for a litigation loss contingency might include, for example, estimates of potential damages, outside legal fees and other directly related costs expected to be incurred. At March 31, 2018 and December 31, 2017, the Company was not involved in any material legal proceedings. Purchase Commitments At March 31, 2018 and December 31, 2017, the Company had no outstanding firm purchase commitments. |
Distribution Agreement
Distribution Agreement | 3 Months Ended |
Mar. 31, 2018 | |
Related Party Transactions [Abstract] | |
Distribution Agreement | 7. Distribution Agreement In December 2014, the Company entered into a distribution agreement with Itochu Corporation, or Itochu, a Japanese entity, pursuant to which the Company appointed Itochu as its exclusive distributor for the sale and delivery of the Company’s MRIdian products within Japan. The exclusive distribution agreement has an initial term of 10 years from December 2014 and contains features customary in these types of distribution agreements. Under this distribution agreement, the Company will supply its products and services to Itochu based upon the Company’s then-current pricing. In consideration of the exclusive distribution rights granted, Itochu agreed to pay a distribution fee of $4.0 million in three installments: (i) the first installment of $1.0 million was due upon execution of the distribution agreement; (ii) the second installment of $1.0 million was due within 10 business days following submission of the application for regulatory approval of the Company’s product to the Japan regulatory authority; and (iii) the final installment of $2.0 million was due within 10 business days following receipt of approval for the Company’s product from the Japanese Ministry of Health, Labor and Welfare. The distribution fee paid by Itochu was refundable if the Company failed to obtain the approval from the Japan regulatory authority before December 31, 2017. The first and second installments of $2.0 million in aggregate were received in December 2014 and December 2015, respectively. In August 2016, the Company received the third and final $2.0 million installment upon the receipt of regulatory approval to market MRIdian in Japan A time-elapsed method is used to measure progress because the control is transferred evenly over the remaining contractual period. |
Equity Financing
Equity Financing | 3 Months Ended |
Mar. 31, 2018 | |
Equity [Abstract] | |
Equity Financing | 8. Equity Financing Private Placements In September 2016, the Company completed the final closing of a private placement offering, or the 2016 Private Placement, through which it sold (i) 4,602,506 shares of its common stock and (ii) warrants that provide the warrant holders the right to purchase 1,380,745 shares of common stock, or the 2016 Placement Warrants, and raised total gross proceeds of $13.8 million. The 2016 Placement Warrants have an exercise price of $2.95 per share, are exercisable at any time at the option of the holder and expire seven years from the date of issuance. In January 2017, the Company completed the final closing of a private placement offering, or the 2017 Private Placement, through which it sold (i) 8,602,589 shares of its common stock and (ii) warrants that provide the warrant holders the right to purchase 1,720,512 shares of common stock, or the 2017 Placement Warrants, and raised total gross proceeds of $26.1 million. The 2017 Placement Warrants have an exercise price of $3.17 per share, became exercisable in July 2017 and expire in January 2024. Direct Registered Offerings In October 2017, the Company entered into Securities Purchase Agreements pursuant to which it sold an aggregate of 8,382,643 shares of common stock for total gross proceeds of $49.9 million, or the October 2017 Direct Registered Offering. The October 2017 Direct Registered Offering was closed on October 25, 2017. In February 2018, the Company entered into a Securities Purchase Agreement pursuant to which it sold (i) 4,090,000 shares of common stock; (ii) 3,000,581 shares of Series A convertible preferred stock and (iii) warrants to purchase 1,418,116 shares of common stock, or the 2018 Offering Warrants for total gross proceeds of $59.1 million, or the March 2018 Direct Registered Offering. The March 2018 Direct Registered Offering was closed on March 5, 2018. The 2018 Offering Warrants have an exercise price of $8.31 per share, became exercisable upon issuance and expire in March 2025. At-The-Market Offering of Common Stock In January 2017, the Company filed a shelf registration statement on Form S-3 with the SEC, which included a base prospectus covering the offering, issuance and sale of up to a maximum aggregate offering of $75.0 million of the Company’s common stock, preferred stock, debt securities, warrants, purchase contracts and/or units and in accordance with Rule 415(a)(4) under the Securities Act FBR acted as sales agent on a best efforts basis and used commercially reasonable efforts to sell on behalf of the Company all of the shares of common stock requested to be sold by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between FBR and the Company. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. In April 2017, the Company agreed to sell up to an additional $25.0 million of the Company’s common stock in accordance with the terms of a sales agreement with FBR and pursuant to an at-the-market offering program in accordance with Rule 415(a)(4) under the Securities Act. FBR is entitled to compensation of up to 3.0% of the gross sales price per share sold. In connection with the sale of the Company’s common stock on the Company’s behalf, FBR is deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of FBR is deemed to be underwriting commissions or discounts. The Company has also agreed to provide indemnification and contribution to FBR with respect to certain liabilities, including liabilities under the Securities Act. In fiscal year 2017, the Company sold an aggregate of 6,575,062 shares of its common stock at an average market price of $6.10 per share, resulting in aggregate gross proceeds of approximately $40.1 million. No securities were sold under the at-the-market offering program in the first quarter of 2018. |
Convertible Preferred Stock
Convertible Preferred Stock | 3 Months Ended |
Mar. 31, 2018 | |
Equity [Abstract] | |
Convertible Preferred Stock | 9. Convertible Preferred Stock In March 2018, the Company issued 3,000,581 shares of Series A convertible preferred stock to an existing investor through the 2018 Direct Registered Offering at a price of $8.31per share (see Note 8). At the date of the financing, because the effective conversion rate of the preferred stock was less than the market value of the Company’s common stock, a beneficial conversion feature of $2.7 million has been recorded as a discount to the convertible preferred stock and an increase to additional paid in capital. Because the preferred stock is perpetual and is convertible at the option of the holder at any time, the Company fully amortized the discount related to the beneficial conversion feature as a deemed dividend which was recognized as an increase to accumulated deficit and net loss attributable to common stockholders. Except as set forth below, each share of Series A convertible preferred stock has the same rights and privileges as a share of common stock, and ranks equally with a share of common stock with respect to any dividend, liquidation, winding up or dissolution of the Company. The rights, privileges and preferences of Series A convertible preferred stock as of March 31, 2018 were as follows: Voting Rights The holders of Series A convertible preferred stock have no voting rights with respect to the election or composition of the Company’s Board of Directors. On all other matters, they are entitled to vote, together with the holders of common stock as a single class on an as converted to common stock basis. Conversion Rights Each share of Series A convertible preferred stock is convertible by holders into a fully paid and non-assessable share of common stock on a one-for-one basis, subject to anti-dilution adjustments (the “Conversion Rate”). Anti-dilution Adjustments of Conversion Rate In the event the Company declares and pays a dividend or makes a distribution on common stock payable in common stock, the Conversion Rate in effect immediately prior to the record date for that dividend or distribution will be adjusted by multiplying that Conversion Rate by a fraction: • the numerator of which shall be the sum of the number of shares of common stock outstanding immediately prior to the record date for such dividend or distribution and the total number of shares of common stock constituting such dividend or distribution; and • the denominator of which shall be the number of shares of common stock outstanding immediately prior to the record date for such dividend or distribution. In the event the Company subdivides or splits the outstanding shares of common stock into a greater number of shares, or combines or reclassifies the outstanding shares of common stock into a smaller number of shares, the Conversion Rate in effect immediately prior to the effective date of such subdivision, split, combination or reclassification will be adjusted by multiplying such Conversion rate by a fraction: • the numerator of which shall be the number of shares of common stock outstanding immediately after such subdivision, split, combination or reclassification; and • the denominator of which shall be the number of shares of common stock outstanding immediately prior to such subdivision, split, combination or reclassification. In the event of any consolidation or merger of the Company pursuant to which the Company’s common stock will be converted into cash, securities or other property, any sale, transfer lease or conveyance to another person of all or substantially all of the Company’s property and assets, any reclassification of the common stock into securities, including securities other than the Company’s common stock, and any statutory exchange of the outstanding shares of common stock for securities of another person (other than in connection with a merger or acquisition), each share of Series A convertible preferred stock outstanding immediately prior to such event will, without the consent of the holders thereof, become convertible into the kind and amount of securities, cash and other property receivable in such event that the holder would have been entitled to receive if the Series A convertible preferred stock had been converted into common stock immediately prior to such event. Dividends Holders of Series A convertible preferred stock rank equally with the common stockholders and are not entitled to any cumulative or noncumulative dividends in preference to the common stockholders. In the event dividends are paid on common stock, dividends will also be paid on all outstanding shares of Series A convertible preferred stock ratably on an as-converted basis. Liquidation Preferences Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, company assets will be distributed pro rata among the holders of Series A convertible preferred stock and common stock, treating all convertible preferred stock as if it were converted to common stock. Redemption The Series A convertible preferred stock is not redeemable. Conversion As of April 19, 2018, all 3,000,581 shares of Series A convertible preferred stock had been converted into an equal number of shares of common stock, and no shares of Series A convertible preferred stock were outstanding. |
Warrants
Warrants | 3 Months Ended |
Mar. 31, 2018 | |
Equity [Abstract] | |
Warrants | 10. Warrants Equity Classified Common Stock Warrants In connection with a debt financing in December 2013, the Company issued warrants to purchase 128,231 shares of its common stock with an exercise price of $5.84 per share. These warrants are exercisable any time at the option of the holder until December 16, 2023. In connection with the merger of the Company and ViewRay Technologies, Inc. in July 2015, or the Merger, in July and August 2015, the Company conducted a private placement offering during which the Company the five-year anniversary of its date of issuance In connection with the March 2018 Direct Registered Offering, the Company issued warrants to purchase 1,418,116 shares of common stock at an exercise price of $8.31 per share, or the 2018 Offering Warrants. These 2018 Offering Warrants became exercisable upon issuance and expire in March 2025. As separate classes of securities were issued in a bundled transaction, the gross proceeds from the March 2018 Direct Registered Offering of $59.1 million was allocated to common stock, Series A convertible preferred stock and the 2018 Offering Warrants based on their respective relative fair value upon issuance. The aggregate fair value of the 2018 Offering Warrants of $7.4 million was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: expected term of seven years, expected volatility of 62.5%, risk-free interest rate of 2.8% and expected dividend yield of 0%. The allocated proceeds from the 2018 Offering Warrants of $6.6 million was recorded in additional paid-in-capital. At March 31, 2018 and December 31, 2017, none of these equity classified warrants had been exercised and they remain outstanding. Liability Classified Common Stock Warrants In connection with the 2016 Private Placement, in August and September 2016, the Company issued warrants, or the 2016 Placement Warrants, that provide the warrant holder the right to purchase 1,380,745 shares of common stock at an exercise price of $2.95 per share. These 2016 Placement Warrants are exercisable at any time at the option of the holder until the seventh anniversary of their date of issuance. The 2016 Placement Warrants also contain protection whereby warrants will expire immediately prior to the consummation of a Change of Control and holders have the right to receive cash in the amount equal to the Black-Scholes value of warrants. A Change of Control is defined as: (i) a merger or consolidation of the Company with another corporation; (ii) the sale, transfer or other disposal of substantially all of the assets or a majority of the Company’s outstanding shares of capital stock; (iii) a purchase or exchange offer accepted by the holders of a majority of the outstanding voting shares of the Company’s capital stock; or (iv) a “person” or “group,” as defined by Section 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended, is or will become the beneficial owner, directly or indirectly, of at least a majority of the voting power of the Company’s capital stock. The 2016 Placement Warrants were accounted for as a liability at the date of issuance and are adjusted to fair value at each balance sheet date, with the change in fair value recorded as a component of other income (expense), net in the condensed consolidated statements of operations. As separate classes of securities were issued in a bundled transaction, the gross proceeds from the 2016 Private Placement of $13.8 million was allocated first to the 2016 Placement Warrants based on its fair value upon issuance, and the residual was allocated to the common stock. The fair value upon issuance of $2.7 million for the 2016 Placement Warrants was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: expected term of seven years, expected volatility of 61.6%, risk-free interest rate of 1.4% and expected dividend yield of 0%. During the three months ended March 31, 2018 and 2017, the Company recorded a gain of $3.6 million and a loss of $6.8 million, respectively, related to the change in fair value of the 2016 Placement Warrants. The fair value of the 2016 Placement Warrants of $6.3 million and $9.9 million at March 31, 2018 and December 31, 2017, respectively, was estimated using the Black-Scholes option pricing model and the following weighted-average assumptions: March 31, 2018 December 31, 2017 2016 Placement Warrant: Expected term (in years) 5.4 5.7 Expected volatility 61.2% 62.1% Risk-free interest rate 2.6% 2.2% Expected dividend yield 0% 0% At March 31, 2018, 1,355,641 shares of the 2016 Placement Warrants had not been exercised and were still outstanding. In connection with the 2017 Private Placement, in January 2017, the Company issued warrants, the 2017 Placement Warrants, that provide the warrant holder the right to purchase 1,720,512 shares of common stock at an exercise price of $3.17 per share. These 2017 Placement Warrants became exercisable in July 2017 and expire in January 2024. As separate classes of securities were issued in a bundled transaction, the gross proceeds from the 2017 Private Placement of $26.1 million was allocated first to the 2017 Placement Warrants based on its fair value upon issuance, and the residual was allocated to the common stock. The fair value upon issuance of $3.4 million for the 2017 Placement Warrants was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: expected term of seven years, expected volatility of 62.9%, risk-free interest rate of 2.2% and expected dividend yield of 0%. During the three months ended March 31, 2018 and 2017, the Company recorded a gain of $4.6 million and a loss of $8.4 million, respectively, related to the change in fair value of the 2017 Placement Warrants. The fair value of the 2017 Placement Warrants of $7.9 million and $12.5 million at March 31, 2018 and December 31, 2017, respectively, was estimated using the Black-Scholes option pricing model and the following weighted-average assumptions: March 31, 2018 December 31, 2017 2017 Placement Warrant: Expected term (in years) 5.8 6.1 Expected volatility 61.3% 62.3% Risk-free interest rate 2.6% 2.3% Expected dividend yield 0% 0% At March 31, 2018, 1,711,123 shares of the 2017 Placement Warrants had not been exercised and were still outstanding. |
Stock-Based Compensation
Stock-Based Compensation | 3 Months Ended |
Mar. 31, 2018 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |
Stock-Based Compensation | 11. Stock-Based Compensation A summary of the Company’s stock option activity and related information is as follows: Options Outstanding Shares Available for Grant Number of Stock Options Outstanding Weighted- Average Exercise Price Weighted- Average Remaining Contractual (Years) Aggregate Intrinsic Value (In thousands) Balance at December 31, 2017 969,783 8,592,747 $ 3.69 7.4 $ 47,864 Additional options authorized 2,706,158 — Options granted (182,244 ) 182,244 8.16 Options exercised — (265,647 ) 1.42 Options canceled 35,717 (35,717 ) 5.62 Balance at March 31, 2018 3,529,414 8,473,627 $ 3.85 7.4 $ 22,906 Vested and exercisable at March 31, 2018 5,132,684 $ 2.87 6.5 $ 18,702 Vested and expected to vest at March 31, 2018 8,207,659 $ 3.80 7.3 $ 22,557 The weighted-average grant date fair value of options granted to employees was $4.75 and $3.10 per share during the three months ended March 31, 2018 and 2017, respectively. The grant date fair value of options vested was $1.1 million and $558 thousand during the three months ended March 31, 2018 and 2017, respectively. Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. The aggregate intrinsic value of options exercised was $1.6 million and insignificant during the three months ended March 31, 2018 and 2017, respectively. At March 31, 2018, total unrecognized compensation cost related to stock-based awards granted to employees, net of estimated forfeitures, was $9.5 million which is expected to be recognized over a weighted-average period of 2.6 years. Determination of Fair Value The determination of the fair value of stock options on the date of grant using an option-pricing model is affected by the estimated fair value of the Company’s common stock, as well as assumptions regarding a number of complex and subjective variables. The variables used to calculate the fair value of stock options using the Black-Scholes option-pricing model include actual and projected employee stock option exercise behaviors, expected price volatility of the Company’s common stock, the risk-free interest rate and expected dividends. Each of these inputs is subjective and generally requires significant judgment to determine. Fair Value of Common Stock Beginning March 31, 2016, the Company’s common stock shares were listed on The NASDAQ Global Market, or NASDAQ. Fair value of the common stock is the adjusted closing price of the Company’s common stock on the trading date on these stock exchanges. Expected Term The expected term represents the period that the Company’s option awards are expected to be outstanding. The Company considers several factors in estimating the expected term of options granted, including the expected lives used by a peer group of companies within the Company’s industry that the Company considers to be comparable to its business and the historical option exercise behavior of its employees, which the Company believes is representative of future behavior. Expected Volatility As the Company has a limited trading history for its common stock, the expected stock price volatility for the Company’s common stock was estimated by taking a combination of the average historic price volatility of the Company’s common stock and industry peers based on daily price observations over a period equivalent to the expected term of the stock option grants. Industry peers consist of several public companies in the Company’s industry which were the same as the comparable companies used in the common stock valuation analysis. The Company intends to continue to consistently apply this process using the same or similar public companies until a sufficient amount of historical information regarding the volatility of its own share price becomes available, or unless circumstances change such that the identified companies are no longer similar to the Company, in which case, more suitable companies whose share prices are publicly available would be used in the calculation. Risk-Free Interest Rate The risk-free interest rate is based on the zero coupon U.S. Treasury notes, with maturities similar to the expected term of the options. Expected Dividend Yield The Company does not anticipate paying any dividends in the foreseeable future and, therefore, uses an expected dividend yield of zero in the Black-Scholes option-valuation model. In addition to the Black-Scholes assumptions discussed immediately above, the estimated forfeiture rate also has a significant impact on the related stock-based compensation. The forfeiture rate of stock options is estimated at the time of grant and revised in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting option forfeitures and records stock-based compensation expense only for those awards that are expected to vest. The fair value of employee stock option was estimated at the date of grant using a Black-Scholes option-pricing model with the following weighted-average assumptions: Three Months Ended March 31, 2018 2017 Expected term (in years) 5.9 6.0 Expected volatility% 61.7% 67.1% Risk-free interest rate% 2.6% 2.1% Expected dividend yield% 0.0% 0.0% Restricted Stock Units From time to time, the Company grants Restricted Stock Units, or RSUs, to its board of directors for their services. These RSUs were fully vested upon issuance and will be released and settled upon termination of the board services or the occurrence of a change in control event. The fair value of RSUs is based on the closing market price of the Company’s common stock on the grant date. In September 2016 and November 2017, the Company granted 112,578 shares and 43,554 shares of RSUs, to its board members and these RSUs had a grant-date fair value of $3.52 and released in December 2017 in connection with the resignation of one board member. In November 2017, the Company granted 12,468 shares of RSUs with a grant-date fair value of $8.02 per share to one executive officer upon his termination. These RSUs were fully vested upon issuance and were released in the first quarter of fiscal 2018. For the three months ended March 31, 2018 and 2017, no RSUs were issued and no stock-based compensation expense related to RSUs was recorded in the accompanying condensed consolidated statements of operations. Stock-Based Compensation Expense Total stock-based compensation expense recognized in the Company’s condensed consolidated statements of operations is classified as follows (in thousands): Three Months Ended March 31, 2018 2017 Research and development $ 203 $ 165 Selling and marketing 127 51 General and administrative 860 553 Total stock-based compensation expense $ 1,190 $ 769 During the three months ended March 31, 2018 and 2017, there were no stock-based compensation expenses capitalized as a component of inventory or recognized in cost of revenue. Stock-based compensation relating to stock-based awards granted to consultants were insignificant during the three months ended March 31, 2018 and 2017. |
Income Tax
Income Tax | 3 Months Ended |
Mar. 31, 2018 | |
Income Tax Disclosure [Abstract] | |
Income Tax | 12. Income Tax The Tax Cuts and Jobs Act , or the 2017 Tax Act, was enacted on December 22, 2017. Among various provisions, the 2017 Tax Act reduces the U.S. federal corporate tax rate from 35% to 21%. The Company recognized the income tax effects of the 2017 Tax Act in its 2017 financial statements in accordance with SEC Staff Accounting Bulletin No. 118 (“SAB 118”), which provides guidance for the application of ASC Topic 740, Income Taxes, in the reporting period in which the 2017 Tax Act was signed into law. As such, the Company’s 2017 financial results reflected the income tax effects of the 2017 Tax Act for which the accounting under ASC Topic 740 was complete and provisional amounts for those specific income tax effects of the 2017 Tax Act for which the accounting under ASC Topic 740 was incomplete but a reasonable estimate could be determined. Upon completion of our 2017 U.S. income tax return in the current year, we may identify additional remeasurement adjustments to our recorded deferred tax assets. We will continue to assess our provision for income taxes as future guidance is issued, but do not currently anticipate significant revisions will be necessary. Any such revisions will be treated in accordance with the measurement period guidance outlined in SAB 118. For the quarter ended March 31, 2018, we have not made any adjustments to the provisional amounts recorded at December 31, 2017. Due to the current operating losses, the Company recorded zero income tax expense during the three months ended March 31, 2018 and 2017, respectively. During these periods, the Company’s activities were limited to U.S. federal and state tax jurisdictions, as it does not have any foreign operations. The federal and state effective tax rate is approximately 22%. Due to the Company’s history of cumulative losses, management concluded that, after considering all the available objective evidence, it is not more likely than not that all of the Company’s net deferred tax assets will be realized. Accordingly, the Company’s deferred tax assets, which includes net operating loss, or NOL, carryforwards and tax credits related primarily to research and development continue to be subject to a valuation allowance as of March 31, 2018. The Company expects to continue to maintain a full valuation allowance until there is sufficient evidence to support recoverability of its deferred tax assets. The Company had unrecognized tax benefits of $1.5 million and $1.1 million at March 31, 2018 and December 31, 2017, respectively. The reversal of the uncertain tax benefits would not affect the effective tax rate to the extent that the Company continues to maintain a full valuation allowance against its deferred tax assets. Unrecognized tax benefits may change during the next 12 months for items that arise in the ordinary course of business. Interest and/or penalties related to income tax matters are recognized as a component of income tax expense. As of March 31, 2018 and December 31, 2017, there were no accrued interest and penalties related to uncertain tax positions. |
Net Loss per Share
Net Loss per Share | 3 Months Ended |
Mar. 31, 2018 | |
Earnings Per Share [Abstract] | |
Net Loss per Share | 13. Net Loss per Share Since the Company was in a loss position for all periods presented, diluted net loss per common share is the same as basic net loss per common share for all periods presented, because the inclusion of all potential common shares outstanding would have an anti-dilutive effect. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented, because including them would have an anti-dilutive effect: Three Months Ended March 31, 2018 2017 Series A convertible preferred stock (if converted) 900,174 — Options to purchase common stock 8,600,707 7,117,452 Common stock warrants 3,819,190 3,103,262 Restricted stock units 137,168 112,578 Total 13,457,239 10,333,292 |
Related Party Transactions
Related Party Transactions | 3 Months Ended |
Mar. 31, 2018 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | 14. Related Party Transactions In December 2004, the Company entered into a licensing agreement with the University of Florida Research Foundation, or UFRF, whereby UFRF granted the Company a worldwide exclusive license to certain of UFRF’s patents in exchange for 33,652 shares of common stock and a 1% royalty, with a minimum $50,000 royalty payment per quarter, from sales of products developed and sold by the Company utilizing the licensed patents. In January 2017, the Company entered into a sales consulting agreement with Puissance Capital Management, or PCM, to assist with business development activities in a key market in Asia. PCM is the investment manager of Puissance Cross Board Opportunities LLP, a stockholder in the Company. Theodore T. Wang, Ph.D., a member of the Company’s board of directors, is the managing member of the general partners of PCM. The sales consulting agreement has a term of one year with a total consideration of $1.3 million. This amount has been fully expensed in the first quarter of 2018. |
Subsequent Events
Subsequent Events | 3 Months Ended |
Mar. 31, 2018 | |
Subsequent Events [Abstract] | |
Subsequent Events | 15. Subsequent Events In April 2018, the Company entered into a lease agreement to lease approximately 24,630 additional square feet of office space located in Mountain View, California. The lease expires on the seventh anniversary of the commencement date, and the Company has the option to extend the term of the lease for a period of 5 years. In April 2018, the Series A convertible preferred stock the Company sold in the March 2018 Direct Registered Offering was converted into common stock (see Note 9). |
Summary of Significant Accoun21
Summary of Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2018 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation The condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or GAAP, and pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. The condensed consolidated financial statements include the accounts of ViewRay, Inc. and its wholly owned subsidiary, ViewRay Technologies, Inc. All inter-company accounts and transactions have been eliminated in consolidation. In the opinion of management, all adjustments, including normal recurring adjustments, considered necessary for a fair presentation of the Company’s unaudited condensed consolidated financial statements, have been included. The results of operations for the three months ended March 31, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018 or any future period. These unaudited condensed consolidated financial statements and their notes should be read in conjunction with the audited consolidated financial statements and related notes for the year ended December 31, 2017. Effective January 1, 2018, the Company adopted Accounting Standard Codification Topic 606, or ASC 606, Revenues from Contracts with Customers, |
Significant Accounting Policies | Significant Accounting Policies The significant accounting policies used in preparation of these condensed consolidated financial statements are disclosed in the notes to consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed with the SEC on March 12, 2018, and have not changed significantly since that filing, except for the impact of the adoption of the new accounting guidance related to revenue recognition. Revenue Recognition The Company derives revenues primarily from the sale of MRIdian systems and related services as well as support and maintenance services on sold systems. The Company accounts for revenue contracts with customers by applying the requirements of ASC 606, which includes the following steps: • Identification of the contract, or contracts, with a customer; • Identification of the performance obligations in the contract; • Determination of the transaction price; • Allocation of the transaction price to the performance obligations in the contract; and • Recognition of revenue when, or as, the Company satisfies a performance obligation. In all sales arrangements, revenues are recognized when control of the promised goods or services are transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those goods or services. For sales of MRIdian systems that the Company is required to install at the customer site, product revenue is recognized upon receipt of customer acceptance. For sales of MRIdian systems for which the Company is not responsible for installing, product revenue is recognized when the entire system is delivered and control of the system is transferred to the customer. For sales of the related support and maintenance services, a time-elapsed method is used to measure progress toward complete satisfaction of performance obligations and service revenue is recognized ratably over the service contract term, which is typically 12 months. Arrangements with Multiple Performance Obligation The Company frequently enters into sales arrangements that include multiple performance obligations, which mainly consist of (i) sale of MRIdian systems, which generally includes installation and embedded software, and (ii) product support, which includes extended service and maintenance. For such arrangements, the Company allocates revenue to each performance obligation based on its relative standalone selling price. The standalone selling price, or SSP, is determined based on observable prices at which the Company separately sells the products and services. If an SSP is not directly observable, the Company will estimate the SSP considering market conditions or internally approved pricing guidelines related to the performance obligations. Product Revenue Product revenue is derived primarily from the sales of MRIdian system. The system contains both software and non-software components that together deliver essential functionality. The Company’s customer contracts generally call for on-site assembly of the system components and system integration. Once the system installation is completed, the Company performs a detailed demonstration with the customer showing that the MRIdian system meets the standard product specifications. After successful demonstration, the customer signs a document indicating customer’s acceptance. For sales of MRIdian systems that the Company is required to install at the customer site, revenue recognition occurs when the customer acknowledges that the system operates in accordance with standard product specifications, the customer accepts the installed unit by signing the acceptance document and the control of the system is transferred to the customer. Certain customer contracts with distributors do not require ViewRay installation at the customer site, and the distributors typically have their own or engage a qualifying third-party certified technician to perform the installation. For sales of MRIdian systems for which the Company is not responsible for installation, revenue recognition occurs when the entire system is delivered and the control of the system is transferred to the customer. Service Revenue Service revenue is derived primarily from maintenance services. The maintenance and support service is a stand-ready obligation which is performed over the term of the arrangement and, as a result, service revenue is recognized ratably over the service period as the customers benefit from the service throughout the service period. Distribution Rights Revenue In December 2014, the Company entered into a distribution agreement with Itochu Corporation pursuant to which it appointed Itochu as its exclusive distributor for the promotion, sale and delivery of MRIdian products within Japan. In consideration of the exclusive distribution rights granted, the Company received $4.0 million, which was recorded as deferred revenue. Starting in August 2016, distribution rights revenue is recognized ratably over the remaining term of the distribution agreement of approximately 8.5 years . The following table presents revenue disaggregated by types and geography (in thousands): Three Months Ended March 31, U.S. 2018 2017 Product $ 13,535 $ — Service 396 879 Total U.S. revenue $ 13,931 $ 879 Outside of U.S. ("OUS") Product $ 11,844 $ — Service 296 229 Distribution rights 119 119 Total OUS revenue $ 12,259 $ 348 Total Product $ 25,379 $ — Service 692 1,108 Distribution rights 119 119 Total revenue $ 26,190 $ 1,227 Contract Balances The timing of revenue recognition, billings and cash collections results in trade receivables, customer deposit, deferred revenues and deferred cost of revenue on the condensed consolidated balance sheets. Customer deposits represent payments received in advance of system installation. For domestic and international sales, advance payments received prior to inventory shipments and customer acceptance are recorded as customer deposits. Advance payments are subsequently reclassified to deferred revenue upon inventory shipment when the title and risk of loss of inventory items transfer to customers. All customer deposits, including those that are expected to be a deposit for more than one year, are classified as current liabilities based on consideration of the Company’s normal operating cycle (the time between acquisition of the inventory components and the final cash collection from customers on these inventory components) which is in excess of one year. Deferred revenue consists of deferred product revenue and deferred service revenue. Deferred product revenue arises from timing differences between the fulfillment of other contract obligation and satisfaction of all revenue recognition criteria consistent with the Company’s revenue recognition policy. Deferred service revenue results from the advance billing for services to be delivered over a period of time. Deferred revenues expected to be realized within one year or normal operating cycle are classified as current liabilities. Deferred cost of revenue consists of cost for inventory items that have been shipped with title and risk of loss transferred to the customer, but the customer acceptance has not been received. Deferred cost of revenue is included as part of current assets as the corresponding deferred product revenue is expected to be realized within one year or normal operating cycle. During the three months ended March 31, 2018 and 2017, the Company recognized $22.2 million and $0.4 million revenue that was included in the deferred revenue balance at the beginning of each reporting period. Practical Expedients Election As part of the Company's adoption of ASC 606, the Company elected to use the practical expedient to expense costs to obtain a contract as incurred when the amortization period would have been one year or less, which mainly includes the Company's internal sales force compensation program. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements In February 2016, the Financial Accounting Standards Board, FASB, issued ASU No. 2016-02, Leases (Topic 842) |
Recently Adopted Accounting Pronouncements | Recently Adopted Accounting Pronouncements In May 2014, the FASB issued ASC 606. Under the standard, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services. Effective January 1, 2018, the Company adopted the requirements of ASC 606 using the full retrospective method. The adoption has no impact on the prior period financial statements, and the related disclosures required by the new standard have been updated in the “Significant Accounting Policies” section above. On January 1, 2018, the Company adopted ASU No.2016-15 , Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments Statement of Cash Flows (Topic 230): Restricted Cash Under ASU 2016-18, restricted cash and restricted cash equivalent amounts are presented along with cash and cash equivalents when reconciling the total beginning and ending amounts shown on the statement of cash flows. The Company reflected the impact of ASU No. 2016-18 to the comparative prior period which resulted in an increase in the beginning and ending cash, cash equivalents and restricted cash of $ In May 2017, the FASB issued ASU No. 2017-09 , Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting In the first quarter of 2018, the Company adopted ASU No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118, |
Summary of Significant Accoun22
Summary of Significant Accounting Policies (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Accounting Policies [Abstract] | |
Schedule of Revenue Disaggregated by Types and Geography | The following table presents revenue disaggregated by types and geography (in thousands): Three Months Ended March 31, U.S. 2018 2017 Product $ 13,535 $ — Service 396 879 Total U.S. revenue $ 13,931 $ 879 Outside of U.S. ("OUS") Product $ 11,844 $ — Service 296 229 Distribution rights 119 119 Total OUS revenue $ 12,259 $ 348 Total Product $ 25,379 $ — Service 692 1,108 Distribution rights 119 119 Total revenue $ 26,190 $ 1,227 |
Balance Sheet Components (Table
Balance Sheet Components (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Balance Sheet Related Disclosures [Abstract] | |
Schedule of Property and Equipment | Property and equipment consisted of the following (in thousands): March 31, 2018 December 31, 2017 Prototype $ 11,938 $ 11,929 Machinery and equipment 9,731 7,831 Leasehold improvements 4,565 4,438 Software 1,120 1,142 Furniture and fixtures 588 558 Property and equipment, gross 27,942 25,898 Less: accumulated depreciation and amortization (14,987 ) (14,334 ) Property and equipment, net $ 12,955 $ 11,564 |
Summary of Intangible Assets | Intangible assets consisted of the following (in thousands): March 31, 2018 December 31, 2017 License cost $ 512 $ 512 Patents 104 104 Intangible assets, gross 616 616 Accumulated amortization (543 ) (538 ) Intangible assets, net $ 73 $ 78 |
Summary of Estimated Future Amortization Expense | At March 31, 2018, the estimated future amortization expense of intangible assets was as follows (in thousands): Year Ending December 31, Estimated Amortization Expense The remainder of 2018 $ 14 2019 19 2020 19 2021 10 2022 3 2023 1 Thereafter 7 Total amortization expense $ 73 |
Schedule of Accrued Liabilities | Accrued liabilities consisted of the following (in thousands): March 31, 2018 December 31, 2017 Accrued payroll and related benefits $ 5,062 $ 3,944 Accrued accounts payable 2,180 2,671 Accrued legal, accounting and governance fees 198 322 Tax payable 401 149 Other 56 121 Total accrued liabilities $ 7,897 $ 7,207 |
Schedule of Deferred Revenue | Deferred revenue consisted of the following (in thousands): March 31, 2018 December 31, 2017 Deferred revenue: Product $ 6,551 $ 18,861 Services 3,234 1,182 Distribution rights 3,228 3,346 Total deferred revenue 13,013 23,389 Less: current portion of deferred revenue (9,670 ) (20,151 ) Noncurrent portion of deferred revenue $ 3,343 $ 3,238 |
Fair Value of Financial Instr24
Fair Value of Financial Instruments (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Fair Value Disclosures [Abstract] | |
Schedule of Fair Value of Financial Liabilities | The following table sets forth the fair value of the Company’s financial liabilities by level within the fair value hierarchy (in thousands): At March 31, 2018 Level 1 Level 2 Level 3 Total 2017 Placement Warrants Liability $ — $ — $ 7,932 $ 7,932 2016 Placement Warrants Liability — — 6,306 6,306 Total $ — $ — $ 14,238 $ 14,238 At December 31, 2017 Level 1 Level 2 Level 3 Total 2017 Placement Warrants Liability $ — $ — $ 12,487 $ 12,487 2016 Placement Warrants Liability — — 9,933 9,933 Total $ — $ — $ 22,420 $ 22,420 |
Summary of Changes in Fair Value of Level 3 Financial Liabilities | The following table sets forth a summary of the changes in fair value of the Company’s Level 3 financial liabilities (in thousands): Three Months Ended March 31, 2018 2017 Fair value, beginning of period $ 22,420 $ 2,723 Issuance of 2017 Placement Warrants — 3,373 Change in fair value of Level 3 financial liabilities (8,182 ) 15,231 Fair value, end of period $ 14,238 $ 21,327 |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Commitments And Contingencies Disclosure [Abstract] | |
Schedule of Future Minimum Lease Payments Under Noncancelable Operating Lease Agreements | At March 31, 2018, the future minimum payments for the operating leases are as follows (in thousands): Year Ending December 31, Future Payments The remainder of 2018 $ 840 2019 1,039 Total future minimum payments $ 1,879 |
Warrants (Tables)
Warrants (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Equity [Abstract] | |
Summary of Assumptions using Black- Scholes Option Pricing Model to estimate fair value | The fair value of the 2016 Placement Warrants of $6.3 million and $9.9 million at March 31, 2018 and December 31, 2017, respectively, was estimated using the Black-Scholes option pricing model and the following weighted-average assumptions: March 31, 2018 December 31, 2017 2016 Placement Warrant: Expected term (in years) 5.4 5.7 Expected volatility 61.2% 62.1% Risk-free interest rate 2.6% 2.2% Expected dividend yield 0% 0% The fair value of the 2017 Placement Warrants of $7.9 million and $12.5 million at March 31, 2018 and December 31, 2017, respectively, was estimated using the Black-Scholes option pricing model and the following weighted-average assumptions: March 31, 2018 December 31, 2017 2017 Placement Warrant: Expected term (in years) 5.8 6.1 Expected volatility 61.3% 62.3% Risk-free interest rate 2.6% 2.3% Expected dividend yield 0% 0% |
Stock-Based Compensation (Table
Stock-Based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |
Summary of Company's Stock Option Activity and Related Information | A summary of the Company’s stock option activity and related information is as follows: Options Outstanding Shares Available for Grant Number of Stock Options Outstanding Weighted- Average Exercise Price Weighted- Average Remaining Contractual (Years) Aggregate Intrinsic Value (In thousands) Balance at December 31, 2017 969,783 8,592,747 $ 3.69 7.4 $ 47,864 Additional options authorized 2,706,158 — Options granted (182,244 ) 182,244 8.16 Options exercised — (265,647 ) 1.42 Options canceled 35,717 (35,717 ) 5.62 Balance at March 31, 2018 3,529,414 8,473,627 $ 3.85 7.4 $ 22,906 Vested and exercisable at March 31, 2018 5,132,684 $ 2.87 6.5 $ 18,702 Vested and expected to vest at March 31, 2018 8,207,659 $ 3.80 7.3 $ 22,557 |
Schedule of Weighted-Average Assumptions Used in Black-Scholes Option-Pricing Model to Estimate Fair Value of Employee Stock Option at Grant Date | The fair value of employee stock option was estimated at the date of grant using a Black-Scholes option-pricing model with the following weighted-average assumptions: Three Months Ended March 31, 2018 2017 Expected term (in years) 5.9 6.0 Expected volatility% 61.7% 67.1% Risk-free interest rate% 2.6% 2.1% Expected dividend yield% 0.0% 0.0% |
Summary of Stock-Based Compensation Expense | Total stock-based compensation expense recognized in the Company’s condensed consolidated statements of operations is classified as follows (in thousands): Three Months Ended March 31, 2018 2017 Research and development $ 203 $ 165 Selling and marketing 127 51 General and administrative 860 553 Total stock-based compensation expense $ 1,190 $ 769 |
Net Loss per Share (Tables)
Net Loss per Share (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Earnings Per Share [Abstract] | |
Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share | Since the Company was in a loss position for all periods presented, diluted net loss per common share is the same as basic net loss per common share for all periods presented, because the inclusion of all potential common shares outstanding would have an anti-dilutive effect. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented, because including them would have an anti-dilutive effect: Three Months Ended March 31, 2018 2017 Series A convertible preferred stock (if converted) 900,174 — Options to purchase common stock 8,600,707 7,117,452 Common stock warrants 3,819,190 3,103,262 Restricted stock units 137,168 112,578 Total 13,457,239 10,333,292 |
Background and Organization - A
Background and Organization - Additional Information (Detail) - USD ($) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2018 | Mar. 31, 2017 | Dec. 31, 2017 | |
Organization Consolidation And Presentation Of Financial Statements [Abstract] | |||
Net loss | $ (4,814) | $ (27,961) | |
Net cash used from operations | (37,454) | $ (11,964) | |
Cash and cash equivalents | $ 78,916 | $ 57,389 |
Summary of Significant Accoun30
Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands | Aug. 31, 2016 | Mar. 31, 2018 | Mar. 31, 2017 | Jan. 01, 2018 |
Significant Accounting Policies [Line Items] | ||||
Deferred revenue, recognized | $ 22,200 | $ 400 | ||
Operating leases future minimum payments due | $ 1,879 | |||
ASU No. 2016-18 | ||||
Significant Accounting Policies [Line Items] | ||||
Increase in cash, cash equivalents and restricted cash | $ 1,100 | |||
Itochu Corporation Agreement | ||||
Significant Accounting Policies [Line Items] | ||||
Remaining term of distribution agreement | 8 years 6 months | 8 years 6 months | ||
Itochu Corporation Agreement | Distribution Rights | ||||
Significant Accounting Policies [Line Items] | ||||
Distribution revenue reclassified as deferred revenue | $ 4,000 | $ 4,000 |
Summary of Significant Accoun31
Summary of Significant Accounting Policies - Summary of Revenue Disaggregated by Types and Geography (Detail) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Disaggregation Of Revenue [Line Items] | ||
Product | $ 25,379 | $ 0 |
Service | 692 | 1,108 |
Distribution rights | 119 | 119 |
Total revenue | 26,190 | 1,227 |
U.S. | ||
Disaggregation Of Revenue [Line Items] | ||
Product | 13,535 | 0 |
Service | 396 | 879 |
Total revenue | 13,931 | 879 |
Outside of U.S. ("OUS") | ||
Disaggregation Of Revenue [Line Items] | ||
Product | 11,844 | 0 |
Service | 296 | 229 |
Distribution rights | 119 | 119 |
Total revenue | $ 12,259 | $ 348 |
Balance Sheet Components - Sche
Balance Sheet Components - Schedule of Property and Equipment (Detail) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Property Plant And Equipment [Line Items] | ||
Property and equipment, gross | $ 27,942 | $ 25,898 |
Less: accumulated depreciation and amortization | (14,987) | (14,334) |
Property and equipment, net | 12,955 | 11,564 |
Prototype | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, gross | 11,938 | 11,929 |
Machinery and Equipment | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, gross | 9,731 | 7,831 |
Leasehold Improvements | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, gross | 4,565 | 4,438 |
Software | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, gross | 1,120 | 1,142 |
Furniture and Fixtures | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, gross | $ 588 | $ 558 |
Balance Sheet Components - Addi
Balance Sheet Components - Additional Information (Detail) - USD ($) | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Balance Sheet Related Disclosures [Abstract] | ||
Depreciation and amortization | $ 653,000 | $ 462,000 |
Amortization of intangible assets | $ 5,000 | $ 5,000 |
Balance Sheet Components - Summ
Balance Sheet Components - Summary of Intangible Assets (Detail) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Finite Lived Intangible Assets [Line Items] | ||
Intangible assets, gross | $ 616 | $ 616 |
Accumulated amortization | (543) | (538) |
Intangible assets, net | 73 | 78 |
License Cost | ||
Finite Lived Intangible Assets [Line Items] | ||
Intangible assets, gross | 512 | 512 |
Patents | ||
Finite Lived Intangible Assets [Line Items] | ||
Intangible assets, gross | $ 104 | $ 104 |
Balance Sheet Components - Su35
Balance Sheet Components - Summary of Estimated Future Amortization Expense (Detail) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Balance Sheet Related Disclosures [Abstract] | ||
The remainder of 2018 | $ 14 | |
2,019 | 19 | |
2,020 | 19 | |
2,021 | 10 | |
2,022 | 3 | |
2,023 | 1 | |
Thereafter | 7 | |
Intangible assets, net | $ 73 | $ 78 |
Balance Sheet Components - Sc36
Balance Sheet Components - Schedule of Accrued Liabilities (Detail) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Payables And Accruals [Abstract] | ||
Accrued payroll and related benefits | $ 5,062 | $ 3,944 |
Accrued accounts payable | 2,180 | 2,671 |
Accrued legal, accounting and governance fees | 198 | 322 |
Tax payable | 401 | 149 |
Other | 56 | 121 |
Total accrued liabilities | $ 7,897 | $ 7,207 |
Balance Sheet Components - Sc37
Balance Sheet Components - Schedule of Deferred Revenue (Detail) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Deferred Revenue [Line Items] | ||
Total deferred revenue | $ 13,013 | $ 23,389 |
Less: current portion of deferred revenue | (9,670) | (20,151) |
Noncurrent portion of deferred revenue | 3,343 | 3,238 |
Product | ||
Deferred Revenue [Line Items] | ||
Total deferred revenue | 6,551 | 18,861 |
Services | ||
Deferred Revenue [Line Items] | ||
Total deferred revenue | 3,234 | 1,182 |
Distribution Rights | ||
Deferred Revenue [Line Items] | ||
Total deferred revenue | $ 3,228 | $ 3,346 |
Fair Value of Financial Instr38
Fair Value of Financial Instruments - Additional Information (Detail) - USD ($) | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] | ||
Change in fair value of Level 3 financial liabilities | $ 8,182,000 | $ (15,231,000) |
Two Thousand Sixteen And Two Thousand Seventeen Private Placement Warrants | ||
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] | ||
Change in fair value of Level 3 financial liabilities | 8,200,000 | $ (15,200,000) |
Transfers between Level 1 to Level 2 | 0 | |
Transfers between Level 2 to Level 1 | 0 | |
Transfers into or out of Level 3 | $ 0 |
Fair Value of Financial Instr39
Fair Value of Financial Instruments - Schedule of Fair Value of Financial Liabilities (Detail) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Placement Warrants Liability | $ 14,238 | $ 22,420 |
2017 Placement Warrants | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Placement Warrants Liability | 7,932 | 12,487 |
2016 Placement Warrants | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Placement Warrants Liability | 6,306 | 9,933 |
Level 1 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Placement Warrants Liability | 0 | 0 |
Level 1 | 2017 Placement Warrants | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Placement Warrants Liability | 0 | 0 |
Level 1 | 2016 Placement Warrants | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Placement Warrants Liability | 0 | 0 |
Level 2 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Placement Warrants Liability | 0 | 0 |
Level 2 | 2017 Placement Warrants | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Placement Warrants Liability | 0 | 0 |
Level 2 | 2016 Placement Warrants | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Placement Warrants Liability | 0 | 0 |
Level 3 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Placement Warrants Liability | 14,238 | 22,420 |
Level 3 | 2017 Placement Warrants | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Placement Warrants Liability | 7,932 | 12,487 |
Level 3 | 2016 Placement Warrants | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Placement Warrants Liability | $ 6,306 | $ 9,933 |
Fair Value of Financial Instr40
Fair Value of Financial Instruments - Summary of Changes in Fair Value of Level 3 Financial Liabilities (Detail) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] | ||
Fair value, beginning of period | $ 22,420 | $ 2,723 |
Change in fair value of Level 3 financial liabilities | (8,182) | 15,231 |
Fair value, end of period | 14,238 | 21,327 |
2017 Placement Warrants | ||
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] | ||
Issuance of Placement Warrants | $ 0 | $ 3,373 |
Debt - Additional Information (
Debt - Additional Information (Detail) - USD ($) | Mar. 31, 2016 | Jun. 26, 2015 | Oct. 31, 2017 | Apr. 30, 2017 | May 31, 2016 | Mar. 31, 2018 |
Debt Instrument [Line Items] | ||||||
Maximum borrowing capacity | $ 50,000,000 | |||||
Current borrowing capacity | $ 15,000,000 | 30,000,000 | $ 15,000,000 | $ 5,000,000 | ||
Remaining borrowing capacity | 20,000,000 | 20,000,000 | ||||
Proceeds from initial public offering | 40,000,000 | |||||
Post Money Valuation Minimum Amount | 120,000,000 | |||||
Debt drawn | $ 30,000,000 | $ 0 | $ 15,000,000 | |||
Debt maturity date | Jun. 26, 2020 | |||||
Interest payment end date | Mar. 31, 2020 | |||||
Frequency of periodic payment | quarterly | |||||
Debt instrument cash interest rate percentage | 12.50% | |||||
Debt instrument cash interest rate percentage | 8.00% | |||||
Deferred payment in-kind interest rate | 4.50% | |||||
Facility fee | 7.00% | |||||
Term loan first amendment description | In March 2016, the Company and CRG executed an amendment to the original terms of the CRG Term Loan such that, with regard to the conditions for borrowing the remaining $20.0 million available under the CRG Term Loan, the Company may, at its election, draw down (i) an amount of either $10.0 million or $15.0 million in up to two advances upon achievement of a minimum of $15.0 million of aggregate product and service revenue during any consecutive 12 month period ending on or before March 31, 2016 and (ii) an additional $5.0 million (or $10.0 million, if the previous draw made was only in an amount of $10.0 million) upon achievement of a minimum of $25.0 million of aggregate product and service revenue during any consecutive 12 month period ending on or before December 31, 2016 and upon execution of the first sales contract of the Company?s second generation product. | |||||
Term loan second amendment description | In April 2017, the Company and CRG executed an amendment to the terms of its CRG Term Loan. Amendments to the CRG Term Loan include availability of the existing $5.0 million tranche at ViewRay’s option through June 30, 2017, the addition of a $15.0 million tranche of borrowing capacity available at ViewRay’s option through September 30, 2017, extension of the interest-only and payment in-kind period, a decrease to the combined 2016 and 2017 revenue covenant and a 1.75% increase to the facility fee | |||||
Additional borrowing capacity | $ 15,000,000 | |||||
Existing capacity extended expiration date | Dec. 31, 2017 | Jun. 30, 2017 | ||||
Additional capacity extended expiration date | Sep. 30, 2017 | |||||
Increase in facility fee | 1.75% | |||||
Term loan third amendment description | In October 2017, the Company and CRG executed another amendment to the terms of its CRG Term Loan, as amended in March 2016 and April 2017. This amendment extended the availability of the existing $15.0 million borrowing capacity through December 31, 2017. | |||||
Term loan fourth amendment description | In February 2018, the Company and CRG executed an amendment to the terms of its CRG Term Loan to decrease the amount of the minimum combined 2016 and 2017 revenue covenant. | |||||
Amount outstanding under the agreement | $ 45,000,000 | |||||
Deferred payment in-kind interest | $ 5,300,000 | |||||
Milestone One | ||||||
Debt Instrument [Line Items] | ||||||
Remaining borrowing capacity | 10,000,000 | |||||
Required minimum gross revenue | 15,000,000 | |||||
Milestone One | Maximum | ||||||
Debt Instrument [Line Items] | ||||||
Remaining borrowing capacity | 15,000,000 | |||||
Debt drawn | 15,000,000 | |||||
Milestone One | Minimum | ||||||
Debt Instrument [Line Items] | ||||||
Debt drawn | 10,000,000 | |||||
Milestone Two | ||||||
Debt Instrument [Line Items] | ||||||
Remaining borrowing capacity | 5,000,000 | |||||
Required minimum gross revenue | 25,000,000 | |||||
Debt drawn | 15,000,000 | |||||
Milestone Two | Maximum | ||||||
Debt Instrument [Line Items] | ||||||
Remaining borrowing capacity | $ 10,000,000 | |||||
First 12 Months | ||||||
Debt Instrument [Line Items] | ||||||
Prepayment penalty | 3.00% | |||||
After Year 1 but on or Before Year 2 | ||||||
Debt Instrument [Line Items] | ||||||
Prepayment penalty | 2.00% | |||||
After Year 2 but on or Before Year 3 | ||||||
Debt Instrument [Line Items] | ||||||
Prepayment penalty | 1.00% | |||||
After Year 3 Thereafter Until Maturity | ||||||
Debt Instrument [Line Items] | ||||||
Prepayment penalty | 0.00% | |||||
MRIdian System | ||||||
Debt Instrument [Line Items] | ||||||
Required minimum gross revenue | $ 25,000,000 |
Commitments and Contingencies -
Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Noncancelable Operating Lease Agreements (Detail) $ in Thousands | Mar. 31, 2018USD ($) |
Operating Leases Future Minimum Payments Due [Abstract] | |
The remainder of 2018 | $ 840 |
2,019 | 1,039 |
Total future minimum payments | $ 1,879 |
Commitments and Contingencies43
Commitments and Contingencies - Additional Information (Detail) - USD ($) | Mar. 31, 2018 | Dec. 31, 2017 |
Commitments And Contingencies Disclosure [Abstract] | ||
Purchase commitments | $ 0 | $ 0 |
Distribution Agreement - Additi
Distribution Agreement - Additional Information (Detail) $ in Thousands | Aug. 31, 2016USD ($) | Aug. 31, 2016USD ($) | Dec. 31, 2014USD ($)Installment | Mar. 31, 2018USD ($) | Mar. 31, 2017USD ($) | Dec. 31, 2015USD ($) | Dec. 31, 2017USD ($) |
Marketing Agreement [Line Items] | |||||||
Distribution fee reclassified to deferred revenue | $ 13,013 | $ 23,389 | |||||
Distribution rights revenue | 119 | $ 119 | |||||
Distribution Rights | |||||||
Marketing Agreement [Line Items] | |||||||
Distribution fee reclassified to deferred revenue | $ 3,228 | $ 3,346 | |||||
Itochu Corporation Agreement | |||||||
Marketing Agreement [Line Items] | |||||||
Distribution agreement term | 10 years | ||||||
Distribution fees | $ 4,000 | ||||||
Number of installments | Installment | 3 | ||||||
Remaining term of distribution agreement | 8 years 6 months | 8 years 6 months | |||||
Distribution rights revenue | $ 119 | $ 119 | |||||
Itochu Corporation Agreement | Distribution Rights | |||||||
Marketing Agreement [Line Items] | |||||||
Distribution fee reclassified to deferred revenue | $ 4,000 | $ 4,000 | |||||
Itochu Corporation Agreement | First Installment | |||||||
Marketing Agreement [Line Items] | |||||||
Distribution fees | $ 1,000 | ||||||
Itochu Corporation Agreement | Second Installment | |||||||
Marketing Agreement [Line Items] | |||||||
Distribution fees | 1,000 | ||||||
Itochu Corporation Agreement | Third Installment | |||||||
Marketing Agreement [Line Items] | |||||||
Distribution fees | $ 2,000 | ||||||
Distribution fees payment | $ 2,000 | ||||||
Itochu Corporation Agreement | First and Second Installment | |||||||
Marketing Agreement [Line Items] | |||||||
Distribution fees payment | $ 2,000 |
Equity Financing - Additional I
Equity Financing - Additional Information (Detail) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||
Feb. 28, 2018 | Oct. 31, 2017 | Jan. 31, 2017 | Sep. 30, 2016 | Aug. 31, 2016 | Mar. 31, 2018 | Mar. 31, 2017 | Sep. 30, 2017 | Dec. 31, 2017 | Apr. 30, 2017 | |
2016 Placement Warrants | ||||||||||
Subsidiary Sale Of Stock [Line Items] | ||||||||||
Warrants to purchase common stock, shares | 1,380,745 | 1,380,745 | ||||||||
Warrant exercise price | $ 2.95 | $ 2.95 | ||||||||
Warrant expiration period | 7 years | 7 years | ||||||||
2017 Placement Warrants | ||||||||||
Subsidiary Sale Of Stock [Line Items] | ||||||||||
Warrants to purchase common stock, shares | 1,720,512 | |||||||||
Warrant exercise price | $ 3.17 | |||||||||
Proceed from private placement and equity issuances, gross | $ 26,100,000 | |||||||||
Warrant exercisable date | Jul. 31, 2017 | |||||||||
Warrant expiration date | Jan. 31, 2024 | |||||||||
At The Market Offering Program | ||||||||||
Subsidiary Sale Of Stock [Line Items] | ||||||||||
Stock issued during period | 0 | |||||||||
Aggregate gross proceeds from issuance of common stock | $ 0 | $ 21,921,000 | $ 40,100,000 | |||||||
Compensation percentage pertaining to gross sales price per share sold | 3.00% | |||||||||
Average market price per share | $ 6.10 | |||||||||
At The Market Offering Program | Maximum | ||||||||||
Subsidiary Sale Of Stock [Line Items] | ||||||||||
Maximum aggregate offering price | $ 75,000,000 | |||||||||
Maximum common stock saleable shares, value | $ 25,000,000 | $ 25,000,000 | ||||||||
At The Market Offering Program | Common Stock | ||||||||||
Subsidiary Sale Of Stock [Line Items] | ||||||||||
Stock issued during period | 6,575,062 | |||||||||
2016 Private Placement | Common Stock | ||||||||||
Subsidiary Sale Of Stock [Line Items] | ||||||||||
Private placement, common shares | 4,602,506 | |||||||||
Proceed from private placement and equity issuances, gross | $ 13,800,000 | |||||||||
2017 Private Placement | Common Stock | ||||||||||
Subsidiary Sale Of Stock [Line Items] | ||||||||||
Private placement, common shares | 8,602,589 | |||||||||
Proceed from private placement and equity issuances, gross | $ 26,100,000 | |||||||||
2017 Direct Registered Offering | ||||||||||
Subsidiary Sale Of Stock [Line Items] | ||||||||||
Aggregate gross proceeds from issuance of common stock | $ 49,900,000 | |||||||||
2017 Direct Registered Offering | Common Stock | ||||||||||
Subsidiary Sale Of Stock [Line Items] | ||||||||||
Stock issued during period | 8,382,643 | |||||||||
2018 Direct Registered Offering | ||||||||||
Subsidiary Sale Of Stock [Line Items] | ||||||||||
Warrants to purchase common stock, shares | 1,418,116 | |||||||||
Warrant exercise price | $ 8.31 | |||||||||
Proceed from private placement and equity issuances, gross | $ 59,100,000 | |||||||||
Warrant expiration date | Mar. 31, 2025 | |||||||||
2018 Direct Registered Offering | Common Stock | ||||||||||
Subsidiary Sale Of Stock [Line Items] | ||||||||||
Stock issued during period | 4,090,000 | |||||||||
2018 Direct Registered Offering | Series A Convertible Preferred Stock | ||||||||||
Subsidiary Sale Of Stock [Line Items] | ||||||||||
Stock issued during period | 3,000,581 |
Convertible Preferred Stock - A
Convertible Preferred Stock - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions | Apr. 19, 2018 | Mar. 31, 2018 | Dec. 31, 2017 |
Convertible Preferred Stock [Line Items] | |||
Preferred stock conversion rate | 100.00% | ||
Preferred stock, shares outstanding | 3,000,581 | 0 | |
Series A Convertible Preferred Stock | Subsequent Event | |||
Convertible Preferred Stock [Line Items] | |||
Convertible preferred stock converted to common stock | 3,000,581 | ||
Preferred stock, shares outstanding | 0 | ||
Series A Convertible Preferred Stock | 2018 Direct Registered Offering | |||
Convertible Preferred Stock [Line Items] | |||
Convertible preferred stock, shares issued | 3,000,581 | ||
Stock price | $ 8.31 | ||
Convertible preferred stock, beneficial conversion feature | $ 2.7 |
Warrants - Additional Informati
Warrants - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands | Aug. 22, 2016 | Jan. 31, 2017 | Sep. 30, 2016 | Aug. 31, 2016 | Aug. 31, 2015 | Jul. 31, 2015 | Mar. 31, 2018 | Mar. 31, 2017 | Dec. 31, 2017 | Dec. 31, 2013 |
Common Stock Warrants [Line Items] | ||||||||||
(Gain) loss related to change in fair value | $ (8,182) | $ 15,231 | ||||||||
Fair value of warrants | $ 14,238 | $ 22,420 | ||||||||
2016 Private Placement | ||||||||||
Common Stock Warrants [Line Items] | ||||||||||
Proceed from private placement and equity issuances, gross | $ 13,800 | |||||||||
Fair value of warrants upon issuance | $ 2,700 | |||||||||
Common Stock Warrants | ||||||||||
Common Stock Warrants [Line Items] | ||||||||||
Warrants issued | 128,231 | |||||||||
Exercise price | $ 5.84 | |||||||||
Common stock warrants, expiration date | Dec. 16, 2023 | |||||||||
2015 Placement Common Stock Warrants | Insiders | ||||||||||
Common Stock Warrants [Line Items] | ||||||||||
Warrants issued | 198,760 | 198,760 | ||||||||
Exercise price | $ 5 | $ 5 | ||||||||
Common stock warrants, expiry term | 5 years | 5 years | ||||||||
2018 Offering Warrants | ||||||||||
Common Stock Warrants [Line Items] | ||||||||||
Warrants issued | 1,418,116 | |||||||||
Exercise price | $ 8.31 | |||||||||
Common stock warrants, expiration date | Mar. 31, 2025 | |||||||||
2018 Offering Warrants | 2018 Direct Registered Offering | ||||||||||
Common Stock Warrants [Line Items] | ||||||||||
Proceed from private placement and equity issuances, gross | $ 59,100 | |||||||||
Fair value of warrants upon issuance | $ 7,400 | |||||||||
Expected term (in years) | 7 years | |||||||||
Expected volatility | 62.50% | |||||||||
Risk-free interest rate | 2.80% | |||||||||
Expected dividend yield | 0.00% | |||||||||
Proceeds from offering warrants | $ 6,600 | |||||||||
2016 Placement Warrants | ||||||||||
Common Stock Warrants [Line Items] | ||||||||||
Warrants issued | 1,380,745 | 1,380,745 | ||||||||
Exercise price | $ 2.95 | $ 2.95 | ||||||||
Common stock warrants, expiry term | 7 years | 7 years | ||||||||
Expected term (in years) | 7 years | 5 years 4 months 24 days | 5 years 8 months 12 days | |||||||
Expected volatility | 61.60% | 61.20% | 62.10% | |||||||
Risk-free interest rate | 1.40% | 2.60% | 2.20% | |||||||
Expected dividend yield | 0.00% | 0.00% | 0.00% | |||||||
(Gain) loss related to change in fair value | $ (3,600) | 6,800 | ||||||||
Fair value of warrants | $ 6,306 | $ 9,933 | ||||||||
Placement warrants outstanding | 1,355,641 | |||||||||
2017 Placement Warrants | ||||||||||
Common Stock Warrants [Line Items] | ||||||||||
Warrants issued | 1,720,512 | |||||||||
Exercise price | $ 3.17 | |||||||||
Proceed from private placement and equity issuances, gross | $ 26,100 | |||||||||
Fair value of warrants upon issuance | $ 3,400 | |||||||||
Expected term (in years) | 7 years | 5 years 9 months 18 days | 6 years 1 month 6 days | |||||||
Expected volatility | 62.90% | 61.30% | 62.30% | |||||||
Risk-free interest rate | 2.20% | 2.60% | 2.30% | |||||||
Expected dividend yield | 0.00% | 0.00% | 0.00% | |||||||
(Gain) loss related to change in fair value | $ (4,600) | $ 8,400 | ||||||||
Fair value of warrants | $ 7,932 | $ 12,487 | ||||||||
Placement warrants outstanding | 1,711,123 | |||||||||
Warrant exercisable date | Jul. 31, 2017 | |||||||||
Common stock warrants, expiry date | Jan. 31, 2024 |
Warrants - Summary of Assumptio
Warrants - Summary of Assumptions to Use Option Pricing Model (Detail) | Aug. 22, 2016 | Jan. 31, 2017 | Mar. 31, 2018 | Dec. 31, 2017 |
2016 Placement Warrants | ||||
Fair Value Inputs Liabilities Quantitative Information [Line Items] | ||||
Expected term (in years) | 7 years | 5 years 4 months 24 days | 5 years 8 months 12 days | |
Expected volatility | 61.60% | 61.20% | 62.10% | |
Risk-free interest rate | 1.40% | 2.60% | 2.20% | |
Expected dividend yield | 0.00% | 0.00% | 0.00% | |
2017 Placement Warrants | ||||
Fair Value Inputs Liabilities Quantitative Information [Line Items] | ||||
Expected term (in years) | 7 years | 5 years 9 months 18 days | 6 years 1 month 6 days | |
Expected volatility | 62.90% | 61.30% | 62.30% | |
Risk-free interest rate | 2.20% | 2.60% | 2.30% | |
Expected dividend yield | 0.00% | 0.00% | 0.00% |
Stock-Based Compensation - Summ
Stock-Based Compensation - Summary of Company's Stock Option Activity and Related Information (Detail) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended |
Mar. 31, 2018 | Dec. 31, 2017 | |
Shares Available for Grant | ||
Shares Available for Grant, Beginning balance | 969,783 | |
Shares Available for Grant, Additional options authorized | 2,706,158 | |
Shares Available for Grant, Options granted | (182,244) | |
Shares Available for Grant, Options canceled | 35,717 | |
Shares Available for Grant, Ending balance | 3,529,414 | 969,783 |
Number of Stock Options Outstanding | ||
Number of Stock Options Outstanding, Beginning balance | 8,592,747 | |
Number of Stock Options Outstanding, Options granted | 182,244 | |
Number of Stock Options Outstanding, Options exercised | (265,647) | |
Number of Stock Options Outstanding, Options canceled | (35,717) | |
Number of Stock Options Outstanding, Ending balance | 8,473,627 | 8,592,747 |
Number of Stock Options Outstanding, Vested and exercisable | 5,132,684 | |
Number of Stock Options Outstanding, Vested and expected to vest | 8,207,659 | |
Weighted- Average Exercise Price | ||
Weighted- Average Exercise Price, Beginning balance | $ 3.69 | |
Weighted- Average Exercise Price, Options granted | 8.16 | |
Weighted- Average Exercise Price, Options exercised | 1.42 | |
Weighted- Average Exercise Price, Options canceled | 5.62 | |
Weighted- Average Exercise Price, Ending balance | 3.85 | $ 3.69 |
Weighted- Average Exercise Price, Vested and exercisable | 2.87 | |
Weighted- Average Exercise Price, Vested and expected to vest | $ 3.80 | |
Weighted- Average Remaining Contractual Life (Years) | ||
Options Outstanding, Weighted- Average Remaining Contractual Life (Years) | 7 years 4 months 24 days | 7 years 4 months 24 days |
Weighted- Average Remaining Contractual Life (Years), Vested and exercisable | 6 years 6 months | |
Weighted- Average Remaining Contractual Life (Years), Vested and expected to vest | 7 years 3 months 19 days | |
Aggregate Intrinsic Value | ||
Aggregate Intrinsic Value | $ 22,906 | $ 47,864 |
Aggregate Intrinsic Value, Vested and exercisable | 18,702 | |
Aggregate Intrinsic Value, Vested and expected to vest | $ 22,557 |
Stock-Based Compensation - Addi
Stock-Based Compensation - Additional Information (Detail) - USD ($) | 1 Months Ended | 3 Months Ended | |||
Dec. 31, 2017 | Nov. 30, 2017 | Sep. 30, 2016 | Mar. 31, 2018 | Mar. 31, 2017 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||
Grant date fair value of options granted, per share | $ 4.75 | $ 3.10 | |||
Grant date fair value of options vested | $ 1,100,000 | $ 558,000 | |||
Aggregate intrinsic value of option exercised | 1,600,000 | ||||
Unrecognized compensation cost | $ 9,500,000 | ||||
Weighted average period for recognition of compensation costs | 2 years 7 months 6 days | ||||
Stock based compensation expenses | $ 1,190,000 | 769,000 | |||
Stock-based compensation expense capitalized | $ 0 | $ 0 | |||
Restricted Stock Units (RSUs) | |||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||
RSUs Granted | 0 | 0 | |||
Stock based compensation expenses | $ 0 | $ 0 | |||
Restricted Stock Units (RSUs) | Board of Directors | |||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||
RSUs Granted | 43,554 | 112,578 | |||
Grant date fair value of RSUs, per share | $ 3.52 | $ 8.02 | $ 3.52 | ||
RSUs Released | 18,964 | ||||
Restricted Stock Units (RSUs) | Executive Officers | |||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||
RSUs Granted | 12,468 | ||||
Grant date fair value of RSUs, per share | $ 8.02 |
Stock-Based Compensation - Sche
Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Black-Scholes Option-Pricing Model to Estimate Fair Value of Employee Stock Option at Grant Date (Detail) | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | ||
Expected term (in years) | 5 years 10 months 25 days | 6 years |
Expected volatility% | 61.70% | 67.10% |
Risk-free interest rate% | 2.60% | 2.10% |
Expected dividend yield% | 0.00% | 0.00% |
Stock-Based Compensation - Su52
Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||
Stock-based compensation expense | $ 1,190 | $ 769 |
Research and Development | ||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||
Stock-based compensation expense | 203 | 165 |
Selling and Marketing | ||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||
Stock-based compensation expense | 127 | 51 |
General and Administrative | ||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||
Stock-based compensation expense | $ 860 | $ 553 |
Income Tax - Additional Informa
Income Tax - Additional Information (Detail) - USD ($) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | Dec. 31, 2017 | |
Income Tax Disclosure [Abstract] | |||
Income tax expense | $ 0 | $ 0 | |
Federal statutory tax rate | 21.00% | 35.00% | |
Federal and state effective tax rate | 22.00% | ||
Unrecognized tax benefits | $ 1,500,000 | $ 1,100,000 | |
Accrued interest and penalties related to uncertain tax positions | $ 0 | $ 0 |
Net Loss Per Share - Anti-Dilut
Net Loss Per Share - Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Detail) - shares | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Anti-dilutive securities excluded from calculation of diluted net loss per share | 13,457,239 | 10,333,292 |
Series A Convertible Preferred Stock (If Converted) | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Anti-dilutive securities excluded from calculation of diluted net loss per share | 900,174 | 0 |
Options To Purchase Common Stock | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Anti-dilutive securities excluded from calculation of diluted net loss per share | 8,600,707 | 7,117,452 |
Common Stock Warrants | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Anti-dilutive securities excluded from calculation of diluted net loss per share | 3,819,190 | 3,103,262 |
Restricted Stock Units (RSUs) | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Anti-dilutive securities excluded from calculation of diluted net loss per share | 137,168 | 112,578 |
Related Party Transactions - Ad
Related Party Transactions - Additional Information (Detail) - USD ($) | 1 Months Ended | ||
Jan. 31, 2017 | Dec. 31, 2014 | Dec. 31, 2004 | |
University Of Florida Research Foundation | Licensing Agreements | |||
Related Party Transaction [Line Items] | |||
Common Stock granted in exchange for licensing | 33,652 | ||
Percentage of royalty payment based on sale | 1.00% | ||
Royalty payment per quarter | $ 50,000 | ||
Investment Manager of Investment Company | Sales Consulting Agreement [Member] | |||
Related Party Transaction [Line Items] | |||
Related party, agreement term | 1 year | ||
Related party, total consideration | $ 1,300,000 |
Subsequent Events - Additional
Subsequent Events - Additional Information (Detail) - Subsequent Event - Lease Agreement - Mountain View, California | 1 Months Ended |
Apr. 30, 2018ft² | |
Subsequent Event [Line Items] | |
Additional office space | 24,630 |
Lease agreement, term of contract | 7 years |
Lease agreement, renewal term | 5 years |